The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).
Criteria:To join this study, participants must have been diagnosed with moderate to severe ulcerative colitis (UC) at least 3 months ago and should have tried at least one standard treatment without enough improvement or had issues tolerating it.
However, people with other types of bowel conditions like Crohn's disease, undefined inflammatory bowel disease, or those who have had major surgery for UC, or might need such surgery during the study period, cannot participate.